KYNTRA BIO, INC. Revenue from Contract with Customer, Excluding Assessed Tax
KYNTRA BIO, INC. (KYNB) reported Revenue from Contract with Customer, Excluding Assessed Tax of -$1.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-13
- KYNTRA BIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was -$1.47M, a 209.35% decline year-over-year.
- KYNTRA BIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $3.74M, a 36.47% increase year-over-year.
- KYNTRA BIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $1.28M, a 59.27% decline year-over-year.
- KYNTRA BIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.08M, a 774.80% increase year-over-year.
- KYNTRA BIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $6.44M, a 78.26% decline from fiscal 2024.
- KYNTRA BIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $29.62M, a 36.71% decline from fiscal 2023.
- KYNTRA BIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $46.80M, a 66.74% decline from fiscal 2022.
- KYNTRA BIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $140.73M, a 40.19% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.47M 10-Q · filed 2026-08-13 | $2.26M 10-Q · filed 2026-08-13 | $3.54M derived: sum of 3 quarters · filed 2026-08-13 | $4.62M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $3.74M 10-Q · filed 2026-05-12 | $5.01M derived: sum of 2 quarters · filed 2026-05-12 | $6.09M derived: sum of 3 quarters · filed 2026-05-12 | $7.44M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.35M derived: sum of 2 quarters · filed 2026-03-16 | $3.70M derived: sum of 3 quarters · filed 2026-08-13 | $6.44M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $1.08M 10-Q · filed 2025-11-10 | $2.42M derived: sum of 2 quarters · filed 2026-08-13 | $5.16M 10-Q · filed 2025-11-10 | $8.30M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $1.35M 10-Q · filed 2026-08-13 | $4.09M 10-Q · filed 2026-08-13 | $7.22M derived: sum of 3 quarters · filed 2026-08-13 | $7.34M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $2.74M 10-Q · filed 2026-05-12 | $5.87M derived: sum of 2 quarters · filed 2026-05-12 | $6.00M derived: sum of 3 quarters · filed 2026-05-12 | $7.00M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $3.26M derived: sum of 2 quarters · filed 2026-03-16 | $4.26M derived: sum of 3 quarters · filed 2026-03-16 | $29.62M 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | $123.00K 10-Q · filed 2025-11-10 | $46.33M 10-Q · filed 2024-11-12 | $1.12M derived: sum of 2 quarters · filed 2025-11-10 | $26.49M 10-Q · filed 2025-11-10 | $152.88M 10-Q · filed 2024-11-12 | -$47.33M derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $998.00K 10-Q · filed 2025-08-11 | $50.64M 10-Q · filed 2024-08-06 | $26.36M 10-Q · filed 2025-08-11 | $106.54M 10-Q · filed 2024-08-06 | -$47.45M derived: sum of 3 quarters · filed 2025-08-11 | -$7.32M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | $25.36M 10-Q · filed 2025-05-12 | $55.90M 10-Q · filed 2024-05-06 | -$48.45M derived: sum of 2 quarters · filed 2025-05-12 | -$8.31M derived: sum of 3 quarters · filed 2025-05-12 | $36.01M derived: sum of 4 quarters · filed 2025-05-12 | |||
| 2023-12-31 | -$73.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$33.68M derived: sum of 2 quarters · filed 2025-03-17 | $10.64M derived: sum of 3 quarters · filed 2025-03-17 | $46.80M 10-K · filed 2025-03-17 | $147.75M 10-K · filed 2024-02-26 | |||
| 2023-09-30 | $40.13M 10-Q · filed 2024-11-12 | $84.45M derived: sum of 2 quarters · filed 2024-11-12 | $120.61M 10-Q · filed 2024-11-12 | $154.98M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $44.32M 10-Q · filed 2024-08-06 | $80.48M 10-Q · filed 2024-08-06 | $114.85M derived: sum of 3 quarters · filed 2024-08-06 | $130.58M derived: sum of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | $36.16M 10-Q · filed 2024-05-06 | $70.53M derived: sum of 2 quarters · filed 2024-05-06 | $86.26M derived: sum of 3 quarters · filed 2024-05-06 | $116.07M derived: sum of 4 quarters · filed 2024-05-06 | ||||
| 2022-12-31 | $34.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $50.10M derived: sum of 2 quarters · filed 2024-02-26 | $79.91M derived: sum of 3 quarters · filed 2024-02-26 | $140.73M 10-K · filed 2024-02-26 | ||||
| 2022-09-30 | $15.73M 10-Q · filed 2023-11-06 | $45.54M derived: sum of 2 quarters · filed 2023-11-06 | $106.37M 10-Q · filed 2023-11-06 | $122.91M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $29.81M 10-Q · filed 2023-08-07 | $90.63M 10-Q · filed 2023-08-07 | $107.18M derived: sum of 3 quarters · filed 2024-02-26 | $263.15M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $60.83M 10-Q · filed 2023-05-08 | $77.37M derived: sum of 2 quarters · filed 2024-02-26 | $233.34M derived: sum of 3 quarters · filed 2024-02-26 | $257.71M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $16.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $172.52M derived: sum of 2 quarters · filed 2024-02-26 | $196.88M derived: sum of 3 quarters · filed 2024-02-26 | $235.31M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $155.97M 10-Q · filed 2022-11-07 | $180.34M derived: sum of 2 quarters · filed 2022-11-07 | $218.77M 10-Q · filed 2022-11-07 | $283.76M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | $24.36M 10-Q · filed 2022-08-08 | $62.79M 10-Q · filed 2022-08-08 | $127.79M derived: sum of 3 quarters · filed 2023-02-27 | $171.82M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-03-31 | $38.43M 10-Q · filed 2022-05-09 | $103.43M derived: sum of 2 quarters · filed 2023-02-27 | $147.46M derived: sum of 3 quarters · filed 2023-02-27 | $190.35M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2020-12-31 | $65.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $109.03M derived: sum of 2 quarters · filed 2023-02-27 | $151.92M derived: sum of 3 quarters · filed 2023-02-27 | $176.32M 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | $44.03M 10-Q · filed 2021-11-09 | $86.92M derived: sum of 2 quarters · filed 2021-11-09 | $111.32M 10-Q · filed 2021-11-09 | $119.30M derived: sum of 4 quarters · filed 2022-03-04 | ||||
| 2020-06-30 | $42.89M 10-Q · filed 2021-08-09 | $67.29M 10-Q · filed 2021-08-09 | $75.26M derived: sum of 3 quarters · filed 2022-03-04 | $108.44M derived: sum of 4 quarters · filed 2022-03-04 | ||||
| 2020-03-31 | $24.40M 10-Q · filed 2021-05-10 | $32.38M derived: sum of 2 quarters · filed 2022-03-04 | $65.55M derived: sum of 3 quarters · filed 2022-03-04 | $257.12M derived: sum of 4 quarters · filed 2022-03-04 | ||||
| 2019-12-31 | $7.97M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-04 | $41.15M derived: sum of 2 quarters · filed 2022-03-04 | $232.71M derived: sum of 3 quarters · filed 2022-03-04 | $256.58M 10-K/A · filed 2022-03-04 | ||||
| 2019-09-30 | $33.17M 10-Q · filed 2020-11-05 | $224.74M derived: sum of 2 quarters · filed 2020-11-05 | $248.60M 10-Q · filed 2020-11-05 | $356.66M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $191.57M 10-Q · filed 2020-08-06 | $215.43M 10-Q · filed 2020-08-06 | $323.48M derived: sum of 3 quarters · filed 2021-03-01 | $352.51M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $23.86M 10-Q · filed 2020-05-07 | $131.92M derived: sum of 2 quarters · filed 2021-03-01 | $160.94M derived: sum of 3 quarters · filed 2021-03-01 | $204.90M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $108.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $137.08M derived: sum of 2 quarters · filed 2021-03-01 | $181.03M derived: sum of 3 quarters · filed 2021-03-01 | $212.96M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $29.03M 10-Q · filed 2019-11-12 | $72.98M derived: sum of 2 quarters · filed 2019-11-12 | $104.90M 10-Q · filed 2019-11-12 | $135.64M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | $43.95M 10-Q · filed 2019-08-08 | $75.88M 10-Q · filed 2019-08-08 | $106.61M derived: sum of 3 quarters · filed 2020-03-02 | $147.16M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | $31.93M 10-Q · filed 2019-05-09 | $62.66M derived: sum of 2 quarters · filed 2020-03-02 | $103.21M derived: sum of 3 quarters · filed 2020-03-02 | $133.48M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $30.74M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $71.29M derived: sum of 2 quarters · filed 2020-03-02 | $101.55M derived: sum of 3 quarters · filed 2020-03-02 | $131.00M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | $40.55M 10-Q · filed 2018-11-08 | $70.82M derived: sum of 2 quarters · filed 2018-11-08 | $100.26M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | $30.27M 10-Q · filed 2018-08-07 | $59.71M 10-Q · filed 2018-08-07 | ||||||
| 2016-12-31 | $183.19M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |